Laura McBride

589 total citations
18 papers, 341 citations indexed

About

Laura McBride is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Laura McBride has authored 18 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 16 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Laura McBride's work include Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (13 papers) and Histone Deacetylase Inhibitors Research (8 papers). Laura McBride is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (13 papers) and Histone Deacetylase Inhibitors Research (8 papers). Laura McBride collaborates with scholars based in United States and Japan. Laura McBride's co-authors include David S. Siegel, Kenneth C. Anderson, Ivy Fearen, Syed Rizvi, Kathleen Colson, Judy H. Chiao, Linda Sun, E. M. O' Reilly, Justin L. Ricker and Paul G. Richardson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Laura McBride

18 papers receiving 330 citations

Peers

Countries citing papers authored by Laura McBride

Since Specialization

Citations

This map shows the geographic impact of Laura McBride's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura McBride with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura McBride more than expected).

Fields of papers citing papers by Laura McBride

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura McBride. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura McBride. The network helps show where Laura McBride may publish in the future.

Co-authorship network of co-authors of Laura McBride

This figure shows the co-authorship network connecting the top 25 collaborators of Laura McBride. A scholar is included among the top collaborators of Laura McBride based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura McBride. Laura McBride is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma 2019 ·Blood ·Meena B. Bansal, David S. Siegel, Jaeil Ahn, Rena Feinman, David H. Vesole, (unknown), Andrew L. Pecora, Elli Gourna Paleoudis, Scott D. Rowley, Michèle L. Donato, Robert Korngold, (unknown), Laura McBride, (unknown), Noa Biran	4
2	A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma 2017 ·Blood ·Noa Biran, Tracy Andrews, Rena Feinman, David H. Vesole, (unknown), (unknown), (unknown), Laura McBride, (unknown), Robert Korngold, David S. Siegel	8
3	Real-world outcomes with panobinostat in patients with penta- and quad-refractory multiple myeloma. 2017 ·Journal of Clinical Oncology ·Noa Biran, David H. Vesole, (unknown), (unknown), (unknown), Linda Schmidt, Laura McBride, (unknown), (unknown), (unknown), (unknown), (unknown), David S. Siegel	2
4	Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma 2016 ·Clinical Lymphoma Myeloma & Leukemia ·Elizabeth Bilotti, David H. Vesole, Laura McBride, Linda Schmidt, Zhijie Gao, (unknown), Ann McNeill, Urszula Bednarz, (unknown), Anthony R. Mato, Thorsten Graef, David S. Siegel	4
5	A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens 2016 ·British Journal of Haematology ·Larysa Sanchez, David H. Vesole, Joshua Richter, Noa Biran, Elizabeth Bilotti, Laura McBride, (unknown), (unknown), David S. Siegel	10
6	Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial 2015 ·Blood ·Larysa Sanchez, Yucai Wang, Laura McBride, Elizabeth Bilotti, David H. Vesole, (unknown), Noa Biran, (unknown), (unknown), Ann McNeill, David S. Siegel	1
7	Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma 2015 ·British Journal of Haematology ·David H. Vesole, Elizabeth Bilotti, Joshua Richter, Ann McNeill, Laura McBride, (unknown), (unknown), Urszula Bednarz, (unknown), J. E. Smith, (unknown), Adolfo Aleman, (unknown), Laura Guerrero, Anthony R. Mato, David S. Siegel	30
8	A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM). 2014 ·Journal of Clinical Oncology ·David H. Vesole, David S. Siegel, (unknown), Ann McNeill, (unknown), Urszula Bednarz, (unknown), Laura McBride, (unknown), (unknown), Adolfo Aleman, (unknown), Laura Guerrero, J. E. Smith, Anthony R. Mato, Elizabeth Bilotti	4
9	Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma 2012 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), David S. Siegel, Laura McBride, Elizabeth Bilotti, Erica Bello, (unknown), (unknown), (unknown), Ann McNeill, David H. Vesole	2
10	The Anion Gap and Routine Serum Protein Measurements in Monoclonal Gammopathies 2011 ·Clinical Journal of the American Society of Nephrology ·Karen H. van Hoeven, (unknown), (unknown), Laura McBride, Elizabeth Bilotti, Ann McNeill, Linda Schmidt, (unknown), David S. Siegel	9
11	Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma, 2011 ·Blood ·(unknown), Elizabeth Bilotti, Laura McBride, Linda Schmidt, Zhijie Gao, (unknown), (unknown), Ann McNeill, Urszula Bednarz, Thorsten Graef, David H. Vesole, David S. Siegel	9
12	A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib 2010 ·Blood ·Paul G. Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel M. Sullivan, Melissa Alsina, Deborah Doss, Laura McBride, (unknown), (unknown), (unknown), Mohamed I. Zaki, Christian Jacques, Kenneth C. Anderson	4
13	Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma 2010 ·Blood ·David S. Siegel, Laura McBride, Elizabeth Bilotti, Linda Schmidt, Zhijie Gao, (unknown), Nikoletta Lendvai, Ann McNeill, (unknown), (unknown), (unknown), Thorsten Graef, David H. Vesole	9
14	A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib. 2009 ·Blood ·Paul Richardson, David S. Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel M. Sullivan, Laura McBride, Deborah Doss, (unknown), Christian Jacques, A. A. Donaldson, Kenneth C. Anderson	27
15	Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies 2009 ·Laboratory Medicine ·(unknown), Laura McBride, Elizabeth Bilotti, Nikoletta Lendvai, (unknown), (unknown), (unknown), Ann McNeill, Linda Schmidt, Karen H. van Hoeven	11
16	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma 2008 ·Leukemia & lymphoma ·Paul G. Richardson, Constantine Mitsiades, Kathleen Colson, E. M. O' Reilly, Laura McBride, Judy H. Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, (unknown), (unknown), Ivy Fearen, Kenneth C. Anderson, David S. Siegel	167
17	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma. 2007 ·Blood ·Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, E. M. O' Reilly, Laura McBride, Judy H. Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, (unknown), (unknown), Ivy Fearen, Kenneth C. Anderson, David S. Siegel	16
18	Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats 1997 ·Developmental Brain Research ·Nirupama Laroia, Laura McBride, Raymond B. Baggs, Ronnie Guillet	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact